Strategic Positioning in Digital Health and Cybersecurity: Capturing Long-Term Value in a Digitized Healthcare Ecosystem AInvest
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
